Vedanta Biosciences to Present at Upcoming Investor Conferences

Rhea-AI Summary

Vedanta Biosciences, a clinical-stage biopharmaceutical company, announced participation in key investor conferences this January. The William Blair Biotech Private Company Conference will be held on January 30, 2023, featuring a virtual fireside chat at 2:00 PM ET. Subsequently, the SVB Securities Global Biopharma Conference will take place from January 31 to February 2, 2023, offering virtual 1x1 meetings. Vedanta Biosciences focuses on developing oral therapies using defined bacterial consortia to treat conditions like C. difficile infection and inflammatory bowel diseases. The company, founded by PureTech Health, holds 60+ patents and emphasizes microbiome research.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences:

William Blair Biotech Private Company Conference
Date: Monday, January 30, 2023
Virtual Fireside chat time: 2:00 PM ET

SVB Securities Global Biopharma Conference
Dates: January 31 - February 2, 2023
Virtual 1x1 meetings only

About Vedanta Biosciences
Vedanta Biosciences is leading the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks. The company’s clinical-stage pipeline includes product candidates being evaluated for the treatment of high-risk C. difficile infection, inflammatory bowel diseases, food allergy, liver disease, and cancer. These investigational therapies are grounded in pioneering research – published in leading journals including Science, Nature, and Cell – to identify beneficial bacteria that live symbiotically within the healthy human gut, fight pathogens and induce a range of potent immune responses. Vedanta Biosciences controls a foundational portfolio of more than 60 patents and has built what it believes is one of the largest libraries of bacteria derived from the human microbiome. Proprietary capabilities include deep expertise in consortium design, vast datasets from human interventional studies, and CGMP-compliant manufacturing of oral Live Biotherapeutic Product (LBP) candidates containing pure, clonally-derived bacterial consortia in powdered form. Vedanta Biosciences was founded by PureTech Health (Nasdaq: PRTC, LSE: PRTC) and a global team of scientific co-founders who pioneered the modern understanding of the cross-talk between the microbiome and the immune system.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005227/en/

Media

Nichole Sarkis

+1 774 278 8273

nichole@tenbridgecommunications.com

Investors

Chris Brinzey

+ 1 617 835 9304

Chris.Brinzey@westwicke.com

Source: Vedanta Biosciences

FAQ

What investor conferences is Vedanta Biosciences participating in January 2023?

Vedanta Biosciences will participate in the William Blair Biotech Private Company Conference on January 30, 2023, and the SVB Securities Global Biopharma Conference from January 31 to February 2, 2023.

What time is Vedanta Biosciences' fireside chat at the William Blair Conference?

The fireside chat will take place at 2:00 PM ET on January 30, 2023.

What are the main focuses of Vedanta Biosciences' clinical-stage pipeline?

Vedanta Biosciences is developing therapies for high-risk C. difficile infection, inflammatory bowel diseases, food allergy, liver disease, and cancer.

Who founded Vedanta Biosciences?

Vedanta Biosciences was founded by PureTech Health and a team of scientific co-founders specializing in microbiome and immune system research.

How many patents does Vedanta Biosciences control?

Vedanta Biosciences controls a foundational portfolio of over 60 patents related to its therapies.